| Equation | (# individuals tested) x (% individuals tested/vaccinated solely because of the program) x (# QALY increase) x ($ QALY) |
| Explanation | This metric estimates the impact of hepatitis B screening, prevention, and vaccinations leading to improved health, estimated in terms of quality-adjusted life years (QALY). Number of individuals vaccinated or tested: Reported by program. Percentage of participants who are vaccinated solely because of the program:
QALY increase: [0.66]. This is the average impact of screenings computed using summary results reported by Hahné et al (2013). $ value per QALY: [$50,000] Benefits are then discounted to present value based on the average age of participation to life expectancy. |
| References | Centers for Disease Control and Prevention. (2018). Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2016. Retrieved from https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS2017.html#:~:text=In%202017%2C%20reported%20hepatitis%20B,to%20the%20estimates%20for%202016. Hahné, S. J., Veldhuijzen, I. K., Wiessing, L., Lim, T.-A., Salminen, M., & Laar, M. van de. (2013). Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infectious Diseases, 13(1). Nayagam, S., Sicuri, E., Lemoine, M., Easterbrook, P., Conteh, L., Hallett, T. B., & Thursz, M. (2017). Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries. BMC Infectious Diseases, 17(Suppl 1). |
HEA006 Hepatitis B screening, prevention, and vaccinations leading to increased quality-adjusted life years (QALY)
